Jos de Man

733 total citations
22 papers, 497 citations indexed

About

Jos de Man is a scholar working on Molecular Biology, Cell Biology and Genetics. According to data from OpenAlex, Jos de Man has authored 22 papers receiving a total of 497 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Cell Biology and 4 papers in Genetics. Recurrent topics in Jos de Man's work include Microtubule and mitosis dynamics (7 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Protein Degradation and Inhibitors (3 papers). Jos de Man is often cited by papers focused on Microtubule and mitosis dynamics (7 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Protein Degradation and Inhibitors (3 papers). Jos de Man collaborates with scholars based in Netherlands, Switzerland and United States. Jos de Man's co-authors include Rogier C. Buijsman, Joost C.M. Uitdehaag, Guido J.R. Zaman, Martine B.W. Prinsen, Jeroen A.D.M. de Roos, Nicole Willemsen‐Seegers, Antoon M. van Doornmalen, Yusuke Kawase, Folkert Verkaar and Kiyoshi Yoshino and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Jos de Man

22 papers receiving 481 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jos de Man Netherlands	13	262	122	64	56	53	22	497
Nicole Willemsen‐Seegers Netherlands	11	229 0.9×	99 0.8×	62 1.0×	49 0.9×	20 0.4×	18	371
Antoon M. van Doornmalen Netherlands	10	196 0.7×	112 0.9×	64 1.0×	44 0.8×	50 0.9×	16	386
Nilla Avanzi Italy	15	459 1.8×	263 2.2×	117 1.8×	139 2.5×	64 1.2×	27	778
Carmela Mazzoccoli Italy	12	347 1.3×	95 0.8×	73 1.1×	50 0.9×	27 0.5×	23	614
Zhaoxi Ding China	6	385 1.5×	369 3.0×	49 0.8×	86 1.5×	35 0.7×	13	689
Quang T. Luong United States	11	419 1.6×	168 1.4×	107 1.7×	62 1.1×	36 0.7×	16	754
Lianshan Zhang China	18	352 1.3×	339 2.8×	35 0.5×	170 3.0×	20 0.4×	38	843
Barri Wautlet United States	9	191 0.7×	119 1.0×	22 0.3×	35 0.6×	22 0.4×	11	414
Debora Soncini Italy	13	272 1.0×	295 2.4×	22 0.3×	21 0.4×	16 0.3×	24	827
Ana Isabel Hernández Spain	18	492 1.9×	96 0.8×	26 0.4×	68 1.2×	10 0.2×	28	828

Countries citing papers authored by Jos de Man

Since Specialization

Citations

This map shows the geographic impact of Jos de Man's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jos de Man with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jos de Man more than expected).

Fields of papers citing papers by Jos de Man

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jos de Man. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jos de Man. The network helps show where Jos de Man may publish in the future.

Co-authorship network of co-authors of Jos de Man

This figure shows the co-authorship network connecting the top 25 collaborators of Jos de Man. A scholar is included among the top collaborators of Jos de Man based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jos de Man. Jos de Man is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Uitdehaag, Joost C.M., et al.. (2025). Abstract 5468: A novel kinase degrader antibody conjugate for the treatment of mCRPC. Cancer Research. 85(8_Supplement_1). 5468–5468. 1 indexed citations

Forster, Nicole, Felix Bachmann, Paul M.J. McSheehy, et al.. (2024). Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination. Frontiers in Oncology. 14. 1447807–1447807. 1 indexed citations

Man, Jos de, et al.. (2024). Abstract 1960: CFON-026 is a potent non-covalent BTK inhibitor suitable for combination therapy with covalent BTK inhibitors for early eradication of resistance mutations. Cancer Research. 84(6_Supplement). 1960–1960. 1 indexed citations

Lane, Heidi A., Felix Bachmann, Paul M.J. McSheehy, et al.. (2022). Abstract 5645: BAL0891: A novel dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division resulting in potent anti-cancer activity. Cancer Research. 82(12_Supplement). 5645–5645. 1 indexed citations

Perez‐Pardo, Paula, Nicole Willemsen‐Seegers, Youri Adolfs, et al.. (2021). Pharmacological validation of TDO as a target for Parkinson’s disease. FEBS Journal. 288(14). 4311–4331. 19 indexed citations

Man, Jos de, Antoon M. van Doornmalen, Nicole Willemsen‐Seegers, et al.. (2021). Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0. Frontiers in Immunology. 11. 609490–609490. 16 indexed citations

Willemsen‐Seegers, Nicole, Joost C.M. Uitdehaag, Jos de Man, et al.. (2020). High-Throughput Fluorescence-Based Activity Assay for Arginase-1. SLAS DISCOVERY. 25(9). 1018–1025. 7 indexed citations

Uitdehaag, Joost C.M., et al.. (2019). Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158. SHILAP Revista de lepidopterología. 4. 100014–100014. 34 indexed citations

Uitdehaag, Joost C.M., Jeroen A.D.M. de Roos, Martine B.W. Prinsen, et al.. (2018). Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017. Molecular Cancer Therapeutics. 18(2). 470–481. 20 indexed citations

10.

Zaman, Guido J.R., Jeroen A.D.M. de Roos, Martine B.W. Prinsen, et al.. (2017). TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers. Molecular Cancer Therapeutics. 16(11). 2609–2617. 40 indexed citations

11.

Uitdehaag, Joost C.M., Jos de Man, Nicole Willemsen‐Seegers, et al.. (2017). Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity. Journal of Molecular Biology. 429(14). 2211–2230. 44 indexed citations

12.

Roos, Jeroen A.D.M. de, Joost C.M. Uitdehaag, Nicole Willemsen‐Seegers, et al.. (2017). Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines. Oncotarget. 8(24). 38309–38325. 26 indexed citations

13.

Uitdehaag, Joost C.M., Jeroen A.D.M. de Roos, Martine B.W. Prinsen, et al.. (2016). Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors. Molecular Cancer Therapeutics. 15(12). 3097–3109. 12 indexed citations

14.

Willemsen‐Seegers, Nicole, Joost C.M. Uitdehaag, Martine B.W. Prinsen, et al.. (2016). Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance. Journal of Molecular Biology. 429(4). 574–586. 37 indexed citations

15.

Uitdehaag, Joost C.M., Jeroen A.D.M. de Roos, Antoon M. van Doornmalen, et al.. (2015). Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. PLoS ONE. 10(5). e0125021–e0125021. 16 indexed citations

16.

Uitdehaag, Joost C.M., Jeroen A.D.M. de Roos, Antoon M. van Doornmalen, et al.. (2015). Abstract 3502: Selective targeting of CTNBB1-, KRAS- or MYC-driven cell growth by combinations of existing drugs. Cancer Research. 75(15_Supplement). 3502–3502. 1 indexed citations

17.

Doornmalen, Antoon M. van, et al.. (2014). High-Throughput Fluorescence-Based Screening Assays for Tryptophan-Catabolizing Enzymes. SLAS DISCOVERY. 19(9). 1266–1274. 38 indexed citations

18.

Uitdehaag, Joost C.M., Jeroen A.D.M. de Roos, Antoon M. van Doornmalen, et al.. (2014). Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use. PLoS ONE. 9(3). e92146–e92146. 78 indexed citations

19.

Uitdehaag, Joost C.M., et al.. (2012). A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. British Journal of Pharmacology. 166(3). 858–876. 80 indexed citations

20.

Ray, Peter C., Jane Wright, Julia Adam, et al.. (2010). Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(4). 1084–1088. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact